This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer
Statement on Schedule TO filed with the Securities and Exchange Commission on April 7, 2026 (together with any amendments or supplements thereto, the “Schedule TO”), by Thailand Merger Sub, Inc., a Delaware corporation
(“Purchaser”) and a wholly owned subsidiary of Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”), Parent and Merck & Co., Inc., a New Jersey corporation
(“Merck”). The Schedule TO relates to the offer by Purchaser to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”) of Terns Pharmaceuticals, Inc., a Delaware
corporation (“Terns”), for $53.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated
April 7, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”) and the related Letter of Transmittal (as it may be amended or supplemented from time to time, the “Letter of
Transmittal” and, together with the Offer to Purchase, the “Offer”), copies of which are attached to the Schedule TO as Exhibits (a)(1)(i) and (a)(1)(ii), respectively.
Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the Schedule TO and the exhibits thereto remain
unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to
such terms in the Schedule TO and the Offer to Purchase.
Items 1 through 9 and Item 11.
The disclosure in the Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information
contained in the Offer to Purchase, is hereby amended and supplemented as follows:
“The Offer and related withdrawal rights expired
as scheduled at one minute following 11:59 p.m., Eastern Time, on May 4, 2026 (such date and time, the “Expiration Time”), and the Offer was not extended. The Depositary has advised Purchaser that, as of the Expiration Time,
100,091,794 Shares had been validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86.36% of the then issued and outstanding Shares. As of the Expiration Time, the number of Shares validly tendered and not
validly withdrawn pursuant to the Offer satisfied the Minimum Condition.
Purchaser has accepted all Shares validly tendered and not
validly withdrawn pursuant to the Offer, and payment of the applicable Offer Price for such Shares will be made promptly after the Expiration Time in accordance with the terms of the Offer and the Merger Agreement.
Following expiration of the Offer and acceptance for payment of the Shares, Purchaser owned sufficient Shares to effect the Merger under
Section 251(h) of the DGCL, without a vote of Terns’ stockholders. Accordingly, following completion of the Offer, Parent and Purchaser effected the Merger in accordance with Section 251(h) of the DGCL, in which Purchaser merged with
and into Terns, with Terns surviving the Merger and continuing as a wholly owned subsidiary of Parent.
At the Effective Time, each Share
issued and outstanding (other than (i) Shares held at the commencement of the Offer and immediately prior to the Effective Time by Terns (or held in Terns’ treasury), Parent, Purchaser, or any other direct or indirect wholly owned
subsidiary of Terns, Parent or Purchaser, (ii) Shares irrevocably accepted for purchase in the Offer and (iii) Dissenting Shares) was converted by virtue of the Merger into the right to receive an amount in cash equal to the Offer Price,
without any interest and subject to any applicable withholding of taxes. The Shares are expected to cease to trade on Nasdaq prior to the opening of business on May 5, 2026 and will be delisted from Nasdaq. Parent and Purchaser intend to take
steps to cause the termination of the registration of the Shares under the Exchange Act and suspend all of Terns’ reporting obligations under the Exchange Act as promptly as practicable.
On May 5, 2026, Merck issued a press release announcing the expiration of the Offer and the consummation of the Merger. The full text of
the press release announcing the expiration of the Offer and the consummation of the Merger is attached as Exhibit (a)(5)(v) to the Schedule TO and is incorporated herein by reference.”
